Möchten Sie immer auf dem neuesten Stand bleiben?
Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.
-
Micron Biomedical makes the Most Innovative Companies List in recognition of clinical, financial and other progress toward needle-free vaccines and drugs.
-
N3 stands for: New. Now. Next. It is a gathering of Canada’s top innovators, builders, and most advanced manufacturing companies.
-
Children were previously required to weigh ≥33 lbs. and <66 lbs. and be at least four years of age to receive neffy 1 mg dose - approval enables families of younger children within the weight range...
-
Sanofi’s Sarclisa subcutaneous formulation administered via on-body injector recommended for EU approval by the CHMP to treat multiple myeloma Recommendation based on positive results demonstrating...
-
TORONTO, March 26, 2026 (GLOBE NEWSWIRE) -- “Ontario’s nearly 100,000 REALTORS® know the true value that homeownership brings. That’s why the Ontario Real Estate Association (OREA) has made it our...
-
ROSELAND, N.J., March 26, 2026 (GLOBE NEWSWIRE) -- Milestone Scientific Inc. (NYSE: MLSS), a leading developer of computerized drug delivery instruments that provide objective, pressure-guided...
-
Milestone announcement at SAGES 2026 underscores accelerating adoption of Versius as CMR prepares for U.S. expansion following recent FDA clearance CAMBRIDGE, UK and TAMPA, FL – March 26, 2026 — CMR...
-
VANCOUVER, British Columbia, March 25, 2026 (GLOBE NEWSWIRE) -- B2Gold Corp. (TSX: BTO, NYSE AMERICAN: BTG, NSX: B2G) (“B2Gold” or the “Company”) is pleased to announce positive exploration drilling...
-
DIJON, France – 25 mars 2026 (06.00 PM CET) – CROSSJECT (ISIN : FR0011716265 ; Euronext : ALCJ), the specialty pharmaceuticals company developing emergency medicines based on its proprietary ZENEO®...
-
Recent Phase 2 topline results demonstrate NS002’s potential for best-in-class epinephrine delivery, with statistically significant improvements in early absorption compared to EpiPen®; pivotal study...